Bevespi Aerosphere (glycopyrronium;formoterol fumarate dihydrate)
- Region
- 🇪🇺 EU
- Active substance
- glycopyrronium;formoterol fumarate dihydrate
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- CHMP opinion
- Thu 18 Oct 2018
- EU approval
- Tue 18 Dec 2018
- Application
- EMEA/H/C/004245
- ATC
- R03AL07
- Official record
- www.ema.europa.eu
Indication
Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Regulatory milestones
No milestones recorded in the last year.
Follow Bevespi Aerosphere
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.